Barclays PLC Arrowhead Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 276,610 shares of ARWR stock, worth $5.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

276,610

Previous 276,610 -0.0%

Holding current value

$5.13 Million

Previous $5.36 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$19.36 - $29.54 $3.24 Million - $4.95 Million	167,556 Added 153.64%	276,610 $5.36 Million
Q2 2024 Aug 14, 2024	SELL	$21.87 - $28.24 $2.5 Million - $3.22 Million	-114,094 Reduced 51.13%	109,054 $2.84 Million
Q1 2024 May 15, 2024	SELL	$27.21 - $39.48 $3.78 Million - $5.48 Million	-138,809 Reduced 38.35%	223,148 $6.38 Million
Q4 2023 Feb 15, 2024	BUY	$21.2 - $31.03 $3.48 Million - $5.1 Million	164,234 Added 83.06%	361,957 $11.1 Million
Q3 2023 Nov 07, 2023	SELL	$26.2 - $36.08 $4.17 Million - $5.74 Million	-159,158 Reduced 44.6%	197,723 $5.31 Million
Q2 2023 Aug 03, 2023	BUY	$25.16 - $41.38 $1.03 Million - $1.69 Million	40,899 Added 12.94%	356,881 $12.7 Million
Q1 2023 May 04, 2023	SELL	$23.68 - $38.51 $549,352 - $893,393	-23,199 Reduced 6.84%	315,982 $8.03 Million
Q4 2022 Feb 13, 2023	BUY	$28.0 - $40.56 $1.14 Million - $1.66 Million	40,884 Added 13.71%	339,181 $13.8 Million
Q3 2022 Nov 03, 2022	BUY	$29.63 - $48.31 $3.16 Million - $5.15 Million	106,537 Added 55.56%	298,297 $9.86 Million
Q2 2022 Aug 12, 2022	BUY	$27.79 - $50.61 $1.27 Million - $2.32 Million	45,851 Added 31.42%	191,760 $6.75 Million
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $4.81 Million - $8.5 Million	-121,413 Reduced 45.42%	145,909 $6.71 Million
Q4 2021 Feb 14, 2022	BUY	$58.09 - $82.51 $2.9 Million - $4.12 Million	49,938 Added 22.97%	267,322 $17.7 Million
Q3 2021 Nov 09, 2021	BUY	$58.38 - $84.96 $602,189 - $876,362	10,315 Added 4.98%	217,384 $13.6 Million
Q2 2021 Aug 13, 2021	SELL	$62.15 - $90.32 $1.08 Million - $1.57 Million	-17,366 Reduced 7.74%	207,069 $17.1 Million
Q1 2021 May 13, 2021	BUY	$61.35 - $90.47 $3.68 Million - $5.43 Million	60,039 Added 36.52%	224,435 $14.9 Million
Q4 2020 Feb 11, 2021	SELL	$43.82 - $85.37 $1.51 Million - $2.95 Million	-34,567 Reduced 17.37%	164,396 $12.6 Million
Q3 2020 Nov 12, 2020	BUY	$33.21 - $51.27 $114,275 - $176,420	3,441 Added 1.76%	198,963 $8.57 Million
Q2 2020 Aug 12, 2020	BUY	$26.12 - $43.27 $250,072 - $414,266	9,574 Added 5.15%	195,522 $8.45 Million
Q1 2020 May 13, 2020	BUY	$20.56 - $63.12 $886,855 - $2.72 Million	43,135 Added 30.2%	185,948 $5.35 Million
Q4 2019 Feb 10, 2020	BUY	$28.14 - $73.01 $907,965 - $2.36 Million	32,266 Added 29.19%	142,813 $9.06 Million
Q3 2019 Nov 14, 2019	SELL	$26.26 - $34.86 $199,129 - $264,343	-7,583 Reduced 6.42%	110,547 $3.12 Million
Q2 2019 Aug 14, 2019	BUY	$17.43 - $28.82 $847,028 - $1.4 Million	48,596 Added 69.89%	118,130 $3.13 Million
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $688,886 - $1.15 Million	57,169 Added 462.35%	69,534 $1.28 Million
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $461,658 - $846,804	-42,985 Reduced 77.66%	12,365 $153,000
Q3 2018 Nov 14, 2018	SELL	$14.0 - $20.3 $123,228 - $178,680	-8,802 Reduced 13.72%	55,350 $1.06 Million
Q2 2018 Aug 14, 2018	SELL	$6.37 - $14.02 $420,547 - $925,600	-66,020 Reduced 50.72%	64,152 $873,000
Q1 2018 May 15, 2018	SELL	$3.72 - $7.64 $74,775 - $153,571	-20,101 Reduced 13.38%	130,172 $938,000
Q4 2017 Feb 14, 2018	BUY	$3.14 - $4.5 $289,847 - $415,386	92,308 Added 159.25%	150,273 $553,000
Q3 2017 Nov 14, 2017	BUY	$1.69 - $4.33 $97,960 - $250,988	57,965	57,965 $251,000

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

91.1M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.96B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account